HC Wainwright Forecasts Harrow’s Q4 Earnings (NASDAQ:HROW)

Harrow, Inc. (NASDAQ:HROW) – Equities research analysts at HC Wainwright boosted their Q4 2027 earnings estimates for shares of Harrow in a research note issued on Wednesday, August 12th. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings per share of $1.07 for the quarter, up from their prior forecast of $1.06. The consensus estimate for Harrow’s current full-year earnings is $0.29 per share.

Several other equities research analysts have also recently weighed in on HROW. Wall Street Zen cut Harrow from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Zacks Research cut Harrow from a “hold” rating to a “strong sell” rating in a research note on Tuesday. Cantor Fitzgerald decreased their target price on Harrow from $91.00 to $88.00 and set an “overweight” rating for the company in a report on Wednesday, May 13th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Harrow in a research note on Monday, July 20th. Finally, BTIG Research reiterated a “buy” rating and issued a $63.00 price target on shares of Harrow in a report on Tuesday. Eight investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $69.43.

Harrow Stock Down 0.2%

NASDAQ HROW opened at $39.36 on Thursday. Harrow has a 1 year low of $28.54 and a 1 year high of $54.85. The stock has a market capitalization of $1.48 billion, a PE ratio of -39.36 and a beta of 0.28. The company has a debt-to-equity ratio of 10.30, a current ratio of 2.48 and a quick ratio of 2.30. The business’s 50-day moving average is $40.72 and its 200 day moving average is $39.92.

Harrow (NASDAQ:HROW) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.28). The firm had revenue of $70.66 million for the quarter, compared to the consensus estimate of $69.84 million. Harrow had a negative net margin of 13.51% and a negative return on equity of 31.83%.

Insider Buying and Selling

In related news, Director Adrienne L. Graves acquired 1,000 shares of the stock in a transaction on Monday, May 18th. The stock was acquired at an average cost of $31.07 per share, for a total transaction of $31,070.00. Following the completion of the acquisition, the director directly owned 1,000 shares of the company’s stock, valued at approximately $31,070. This represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 12.80% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in HROW. University of Texas Texas AM Investment Management Co. purchased a new position in shares of Harrow in the 4th quarter valued at approximately $26,000. KBC Group NV bought a new stake in shares of Harrow during the first quarter valued at approximately $31,000. Raymond James Financial Inc. purchased a new stake in Harrow in the second quarter worth $48,000. SBI Securities Co. Ltd. grew its stake in Harrow by 393.5% in the fourth quarter. SBI Securities Co. Ltd. now owns 1,061 shares of the company’s stock worth $52,000 after purchasing an additional 846 shares during the period. Finally, State of Wyoming bought a new position in Harrow in the second quarter worth $72,000. Institutional investors own 72.76% of the company’s stock.

Harrow Company Profile

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.